Olema Pharmaceuticals, INC

Olema Pharmaceuticals and Bayer Consumer Care AG have entered into a clinical trial collaboration to evaluate Olema's OP-3136 in combination with Bayer's NUBEQA for metastatic castration-resistant prostate cancer.

Olema Pharmaceuticals announced encouraging preliminary clinical data from its Phase 1 study of OP-3136, a KAT6 inhibitor, showing good tolerability and anti-tumor activity across multiple solid tumor types.

Olema Pharmaceuticals announced its first quarter 2026 financial and operating results, highlighting progress in its breast cancer pipeline with key clinical trial data expected soon.

Olema Pharmaceuticals has entered into a seven-year lease agreement for new office and lab space in South San Francisco.

Olema Pharmaceuticals announced the appointment of Dr. Prakash Raman to its Board of Directors, effective April 28, 2026, bringing extensive biopharmaceutical industry experience.

Olema Pharmaceuticals reported its full-year 2025 financial and operating results, highlighting progress in its pivotal Phase 3 trials for palazestrant and a strengthened balance sheet.

Olema Pharmaceuticals has entered into a lease agreement for a new corporate headquarters in South San Francisco, California.

Olema Pharmaceuticals reports a significant increase in net losses for Q3 and the first nine months of 2025, driven by expanded R&D for its breast cancer pipeline, while maintaining sufficient liquidity for the next 12 months.

Olema Pharmaceuticals progresses its lead breast cancer therapies through late-stage trials while reporting increased R&D expenses and net losses in Q2 2025.

Olema Pharmaceuticals reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic collaborations.

Olema Pharmaceuticals reports a net loss of $34.6 million for the third quarter of 2024, alongside updates on clinical trials and financial status.

Olema Pharmaceuticals reports a net loss of $30.4 million for the second quarter of 2024, while advancing its clinical programs and securing additional financing.

Olema Pharmaceuticals progresses lead product candidate palazestrant into pivotal Phase 3 trials and initiates Phase 1 for OP-3136, while reporting continued net losses for 2025.

Olema Pharmaceuticals reports its 2024 financial results, highlighting progress in clinical trials for palazestrant and OP-3136, and outlines its strategic focus on developing next-generation targeted therapies for breast cancer.

Olema Pharmaceuticals' 10-K filing details the company's financial status and progress in developing targeted therapies for women's cancers, including palazestrant and OP-3136.

Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc., sold 25,000 shares of common stock on July 23, 2026.

Director Prakash Raman was granted stock options for 27,061 shares of Olema Pharmaceuticals common stock.

Olema Pharmaceuticals' Chief Legal Officer, Shawnte Mitchell, exercised stock options and subsequently sold a total of 40,000 shares of common stock.

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, was granted 356,250 stock options, including performance-based awards, on February 2, 2026.

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, was granted 356,250 stock options, including performance-based awards, effective February 2, 2026.

Olema Pharmaceuticals, Inc. has granted its Chief Legal Officer, Shawnte Mitchell, 276,250 stock options with a $25.65 exercise price, including performance-based awards.

Olema Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, approve executive compensation, and ratify auditor selection.

Olema Pharmaceuticals will hold its annual stockholder meeting virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.

Olema Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, executive compensation, and auditor ratification.

Olema Pharmaceuticals announces its annual stockholder meeting to be held virtually on June 13, 2024, with proposals including the election of directors, executive compensation approval, and ratification of the company's independent auditor.

Olema Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on director elections, executive compensation, and auditor ratification.

Logos Global Management LP and affiliated entities have filed an amended Schedule 13D for Olema Pharmaceuticals, Inc., reporting a decrease in their beneficial ownership to 4.7% due to an increase in the Issuer's outstanding shares, while maintaining their investment for strategic purposes.

Bain Capital Life Sciences Opportunities IV, L.P. has filed an amendment reporting beneficial ownership of 8.15% of Olema Pharmaceuticals, Inc. common stock.

Janus Henderson Group plc has reported beneficial ownership of 7,108,488 shares, representing 8.2% of the outstanding common stock of Olema Pharmaceuticals, Inc.

Raymond Debbane and affiliated entities, including Invus Public Equities, report a combined beneficial ownership of 5.1% in Olema Pharmaceuticals, Inc.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.5% beneficial ownership stake in Olema Pharmaceuticals Inc. common stock.

Deep Track Capital and its affiliates report 0% beneficial ownership in Olema Pharmaceuticals, Inc., indicating a full divestment of their prior stake.

FMR LLC and Abigail P. Johnson have reported a 6.3% beneficial ownership stake in Olema Pharmaceuticals Inc. common stock as of December 31, 2025.